Annexon reports inducement grant to new employee under nasdaq listing rule 5635(c)(4)

Brisbane, calif., nov. 17, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to a new non-executive employee under the terms of the 2022 employment inducement award plan. the equity award was approved on november 16, 2022, in accordance with nasdaq listing rule 5635(c)(4).
ANNX Ratings Summary
ANNX Quant Ranking